SBP 101

Drug Profile

SBP 101

Alternative Names: SBP101; SUN 101

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator University of Florida
  • Developer Sun BioPharma
  • Class Antineoplastics; Polyamines
  • Mechanism of Action Apoptosis stimulants; Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer

Most Recent Events

  • 23 May 2016 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in USA before May 2016 (SC) (NCT02657330)
  • 06 Jan 2016 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in Australia (ACTRN12615000606583) (SC)
  • 09 Nov 2015 SBP 101 receives Orphan Drug status for Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top